DiagnaMed Accelerates Commercialization Initiatives of CERVAI™ Brain Health AI Solution
Based on research and development at Drexel University and the University of Miami, CERVAI™ combines a Brain Age™ Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues.
- Based on research and development at Drexel University and the University of Miami, CERVAI™ combines a Brain Age™ Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues.
- CERVAI™ can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals.
- Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions.
- Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We are pleased to be accepted into the HEALTHI program to accelerate our commercialization initiatives of CERVAI™, a novel brain health AI platform, and validate its potential in improving overall brain health.